Non-medical switching of antiepileptic drugs in epilepsy: clinical risks and consensus recommendations for their minimization. Resolution of the Central Federal District Board of Experts in Neurology and Epileptology (March 28, 2026)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

References

  1. Badalyan O.L., Bogomazova M.A., Zhuravleva I.I. et al. Experience with the use of generic lamotrigine in various forms of epilepsy (results of a focused observation in outpatient health care facilities of Moscow). Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2012;4(4):40–8. (In Russ.).
  2. Barkhatov M.V., Bakhtin I.S., Belyaev O.V., Yamin M.A. Evaluation of the efficacy and tolerability of lamotrigine (Seizar®) in the treatment of idiopathic generalized epilepsy in women: a multicenter study. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2021;13(4):325–37. (In Russ.).
  3. Vorobyova O.V. Treatment of post-stroke epilepsy: experience with Seizar, evaluation of efficacy and safety. Vestnik epileptologii = Bulletin of Epileptology 2024;(1):25–34. (In Russ.).
  4. Karlov V.A. Epilepsy and the woman – the woman has been found! (based on the materials of the conference with international participation “Epilepsy and the woman”, October 5–6, 2021, Belgrade). Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2022;14(3):227–41. (In Russ.).
  5. Clinical guidelines “Epilepsy and status epilepticus in adults and children”. 2022. Available at: https://cr.minzdrav.gov.ru/schema/741. (In Russ.).
  6. Larina I.V. Current issues of pregnancy management in patients with epilepsy. Vestnik epileptologii = Bulletin of Epileptology 2021;2021:36–47. (In Russ.).
  7. Mukhin K.Yu., Pylaeva O.A., Bobylova M.Yu., Freidkova N.V. Lamotrigine (Seizar) in the treatment of epilepsy: results of 4-year use of the drug in the Svt. Luka’s Association of Medical Institutions for the Diagnosis, Treatment, and Rehabilitation of Diseases of the Nervous System and Epilepsy. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2022;17(3):8–35. (In Russ.). doi: 10.17650/2073-8803-2022-17-3-8-36
  8. Effectiveness, safety and assessing the results of drug therapy in patients with epilepsy. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2021;13(3):306–10. (In Russ.). doi: 10.17749/2077-8333/epi.par.con.2021.093
  9. Pivovarova A.M., Gorchkhanova Z.K. Evaluation of the efficacy and tolerability of lamotrigine (Seizara) in mono- and polytherapy for generalized and focal epilepsies. Experience with lamotrigine (Seizara) use at the Veltischev Research Institute of Pediatrics in 2019–2021. Vestnik epileptologii = Bulletin of Epileptology 2021;2021:19–29. (In Russ.).
  10. Resolution of the expert meeting of the Russian Anti-Epileptic League on the treatment of women with epilepsy. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2019;11(2):195–9. (In Russ.).
  11. Recommendations of the expert council of the Russian Anti-Epileptic League on the use of original and generic drugs for the treatment of epilepsy. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2011;3(1):17–9. (In Russ.).
  12. Rudakova I.G., Kotov A.S., Belova Yu.A. Use of generic drugs in the treatment of epilepsy: example of topiramate. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2011;111(3):38–43. (In Russ.).
  13. Rudakova I.G. Treatment of epilepsy in a reciprocal regimen and the quality of epilepsy control – current issues in clinical practice. Focus – lamotrigine. Vestnik epileptologii = Bulletin of Epileptology 2023;(1):19–29. (In Russ.).
  14. Rudakova I.G. Remote results of switching to generic analogs of topiramate in patients with epilepsy. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2013;5(2):6–10. (In Russ.).
  15. Ulyakov A.N., Pylaeva O.A. Seizure control issues associated with substitutions of antiepileptic drugs within the INN framework: focus on lamotrigine (literature review and clinical cases). Vestnik epileptologii = Bulletin of Epileptology 2025;2025:34–44. (In Russ.).
  16. Shestakova O.I., Aksenov S.I. Epilepsy spectrum in patients receiving lamotrigine: focus on focal epilepsies (analysis of own data). Vestnik epileptologii = Bulletin of Epileptology 2022;2022:59–70. (In Russ.).
  17. Atif M., Azeem M., Sarwar M.R. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. Springerplus 2016;5:182. doi: 10.1186/s40064-016-1824-2
  18. Berg M.J., Gross R.A., Tomaszewski K.J. et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008;71:525–30.
  19. Bialer M., Levy R.H., Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit 1998;20:56–9. doi: 10.1097/00007691-199802000-00010
  20. Bialer M., Midha K. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia 2010;51(6):941–50. doi: 10.1111/j.1528-1167.2010.02573.x
  21. Fahoum F., Linder I., Herskovitz M. et al. Generic substitutions of antiseizure medications: recommendations issued by the Israeli Chapter of the International League Against Epilepsy. Epileptic Disord 2022;24(5):973–5. doi: 10.1684/epd.2022.1469.
  22. Gilad R., Sadeh M., Rapoport A. et al. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007;30:189–95 doi: 10.1097/WNF.0b013e3180333069
  23. Holtkamp M., Theodore W.H. Generic antiepileptic drugs – safe or harmful in patients with epilepsy? Epilepsia 2018;59(7):1273–81. doi: 10.1111/epi.14439
  24. Houben E., Benson R.J., Steegers E.A.P., Herings R.M.C. Twenty-year trends in the use of anti-seizure medication among pregnant women in the Netherlands. Epilepsy Behav 2022;127:108549. doi: 10.1016/j.yebeh.2021.108549
  25. Jung N.H., Egert-Schwender S., Schossow B. et al. Improvement of synaptic plasticity and cognitive function in RASopathies – a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial (SynCoRAS). Trials 2023;24(1):383. doi: 10.1186/s13063-023-07392-z
  26. MHRA. Antiepileptics: changing products (last modified November 25, 2013). Available at: https://www.gov.uk/drug-safety-update/antiepileptic-drugs-updated-advice-on-switching-between-different-manufacturers-products.
  27. Midha K., McKay G. Bioequivalence; its history, practice, and future. AAPS J 2009;11(4):664–70. doi: 10.1208/s12248-009-9142-z
  28. Nagabushana D., Eslami F., Loeb J.A. Seizure medications and interictal spiking: implications for cognition and behavior. Epilepsia 2026. doi: 10.1002/epi.70102
  29. NICE. Epilepsies: diagnosis and management. Clinical guideline. Available at: https://www.nice.org.uk/guidance/ng217.
  30. Stephen L.J., Wishart A., Brodie M.J. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav 2017;71(Pt A):73–8. doi: 10.1016/j.yebeh.2017.04.003
  31. Tomson T., Battino D., Bonizzoni E. et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP Registry. EURAP Study Group. Lancet Neurol 2018;17(6):530–8. doi: 10.1016/S1474-4422(18)30107-8
  32. US FDA. Understanding generic drugs. Available at: http://www.fda.gov/drugs/ resourcesforyou/consumers/buyingusingmedicinesafely/understandinggenericdrugs/ucm167991.html.
  33. Werhahn K.J., Trinka E., Dobesberger J. et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015;56(3):450–9. doi: 10.1111/epi.12926
  34. Yamada M., Welty T.E. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother 2011;45(11):1406–15.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-90927 от  13.02.2026.